Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations

Journal of Medical Virology

Volumn 65, Issue 2, 2001, Pages 218-224

  Devereux, Helen L ^a,b   Emery, Vincent C ^a   Johnson, Margaret A ^a   Loveday, Clive ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MEDITECH MEDIA LTD   (United Kingdom)

Author keywords

Genotypic; Protease; Reverse transcriptase; Therapy; Virus

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; VIRUS GENE; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CODON; COHORT STUDIES; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HOMOSEXUALITY; HUMANS; MALE; MIDDLE AGED; MUTATION; VIRUS REPLICATION;

EID: 0034867418     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2023     Document Type: Article

References (26)

1. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
2. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
3. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
4. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
5. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
6. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents
7. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
8. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
9. The dynamics of human cytomegalovirus replication in vivo
10. Evolution of lamivudine resistance in human immunodeficiency virus type 1- infected individuals: The relative roles of drift and selection
11. Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
12. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215
13. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
14. Antiretroviral drug resistance testing in adults with HIV infection
15. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses
16. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
17. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing
18. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance
19. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
20. Mega-HAART, resistance and drug holidays
21. Clinical significance of drug resistance in human immunodeficiency virus
22. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials: Compensatory modulations of binding and activity
23. Strategies in the treatment of AIDS and related diseases: The lessons of cancer chemotherapy
24. Surrogate marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors and nucleoside analogues in protease inhibitor failures
25. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo